FC
APGE icon

FORA Capital’s Apogee Therapeutics APGE Stock Holding History

FORA Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$598K Sell
7,099
-11,101
-61% -$806K 0.04% 289
2025
Q4 		$1.37M Buy
+18,200
New +$1.15M 0.17% 162
2024
Q4 		– Sell
-6,789
Closed -$399K – 386
2024
Q3 		$399K Buy
+6,789
New +$325K 0.05% 327

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FORA Capital's APGE Position: Q1 2026 in Review

FORA Capital reduced its Apogee Therapeutics (APGE) stake by 61% in Q1 2026, selling an estimated $806K and leaving 7,099 shares worth $598K. The position accounts for 0.04% of the portfolio, ranked #289.

FORA Capital first reported a position in APGE in Q3 2024 and has held it in 3 quarters since. The position peaked at $1.37M in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • FORA Capital held 7,099 shares of Apogee Therapeutics worth $598K as of Q1 2026.
  • FORA Capital sold 11,101 Apogee Therapeutics shares in Q1 2026, an estimated $806K.
  • Apogee Therapeutics made up 0.04% of FORA Capital's portfolio in Q1 2026, its #289 holding.
  • FORA Capital first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • FORA Capital's Apogee Therapeutics position peaked at $1.37M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.